Clinical trials
Terminated Stomach Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
207 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 1 |
| 2002 | 2 |
| 2003 | 2 |
| 2004 | 6 |
| 2005 | 5 |
| 2006 | 6 |
| 2007 | 11 |
| 2008 | 5 |
| 2009 | 6 |
| 2010 | 4 |
| 2011 | 10 |
| 2012 | 10 |
| 2013 | 9 |
| 2014 | 7 |
| 2015 | 10 |
| 2016 | 7 |
| 2017 | 10 |
| 2018 | 9 |
| 2019 | 18 |
| 2020 | 22 |
| 2021 | 14 |
| 2022 | 17 |
| 2023 | 7 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 207 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 11 |
| Amgen | 6 |
| Hoffmann-La Roche | 6 |
| Pfizer | 5 |
| Seagen Inc. | 4 |
| Fudan University | 3 |
| Merck Sharp & Dohme LLC | 3 |
| Stanford University | 3 |
| Alliance for Clinical Trials in Oncology | 2 |
| AstraZeneca | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Stomach Neoplasms | 207 |
| Esophageal Neoplasms | 58 |
| Carcinoma, Non-Small-Cell Lung | 37 |
| Colorectal Neoplasms | 37 |
| Pancreatic Neoplasms | 33 |
| Breast Neoplasms | 32 |
| Ovarian Neoplasms | 29 |
| Neoplasms | 24 |
| Colonic Neoplasms | 23 |
| Lung Neoplasms | 20 |
Trials
Showing 26 to 50 of 207. Each trial links to its page on Pharma Observatory.
107 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.